Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES-PET Reproducibility and Prediction in Metastatic Breast Cancer
NCT03065712Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Feb 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluoroestradiol f 18 in breast cancer, sponsored by UT Southwestern Medical Center. Planned start Feb 2017; status: withdrawn.
02
Drugs
fluoroestradiol f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03065712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065712.